Scilex Holding Company Warrant (SCLXW)

• Market cap: $1.33M
• 1 day: 0.70%
• 5 days: 3.71%
• 1 month: 0.70%
• 3 months: 62.42%
• 6 months: -60.89%
• Year to date: -52.05%
• 1 year: -74.32%
• 5 years: -82.70%
• 10 years: -82.70%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Employees: 111

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.01% more ownership

Funds ownership: 1.85% [Q4 2024] → 1.86% (+0.01%) [Q1 2025]

13% less funds holding

Funds holding: 8 [Q4 2024] → 7 (-1) [Q1 2025]

45% less capital invested

Capital invested by funds: $73.1K [Q4 2024] → $39.9K (-$33.3K) [Q1 2025]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2